News >

Expert Details Latest Data Across GI Cancers

Caroline Seymour
Published: Monday, Aug 06, 2018

Susanna Ulahannan, MD

Susanna Ulahannan, MD

Among the gastrointestinal (GI) cancer findings presented at the 2018 ASCO Annual Meeting, the phase III PRODIGE 24/CCTG PA.6 trial results were the most significant, said Susanna Ulahannan, MD.

State of the Science Summit,™ A Summer of Progress: Updates from ASCO 2018, Ulahannan, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, highlighted these trials from the 2018 ASCO Annual Meeting across GI malignancies and future therapeutic approaches across the landscape.

OncLive: Can you discuss the importance of the PRODIGE 24 trial?

Ulahannan: The PRODIGE 24 trial in pancreatic cancer…was done in France and Canada and has changed the standard of care. The OS in pancreatic cancer, even in resectable cancer, is poor. What we have seen in trials prior in the adjuvant setting was an OS of 24 months. [We saw an OS of] 28 months in the last standard of care with gemcitabine and capecitabine.

The mFOLFIRINOX regimen that was presented at the 2018 ASCO Annual Meeting had an OS of 54.5 months, which is remarkable. We haven't seen any data like these before. From a GI perspective, that was the most exciting data from that meeting.

Can you elaborate on the other PRODIGE trials that were presented?

There was also a PRODIGE study in the maintenance setting in pancreatic cancer. The initial PRODIGE study looking at FOLFIRINOX in metastatic pancreatic cancer was the first one that showed an OS of more than 11 months in the metastatic setting. That is the standard of care now. However, that's a toxic regimen. The investigators went back to see if there was something we could do to make it more tolerable for our patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x